Mexico’s Pharmaceutical Industry: A New Era of Growth and Export Potential
Astrea Ocampo, the newly appointed president of the Mexican Association of Pharmaceutical Laboratories (AMELAF), has issued a strong call to the federal government for policies that will stimulate investment and propel the growth of the nation’s pharmaceutical companies. This comes at a pivotal moment, with the industry poised to become a significant exporter and a key driver of economic development.
Streamlining Regulations: A Top Priority
Ocampo’s primary request centers on simplifying bureaucratic processes for companies investing in Mexico. She acknowledged the current economic climate, stating, “I know there will be no funding, I know there will be no subsidies. Enable us with a lane where the procedures for these companies investing in the country can achieve certain facilities.” This plea highlights a critical need for efficiency in regulatory approvals and administrative procedures.
The focus isn’t on altering existing regulations, but rather on adding mechanisms to expedite processes. This is particularly important for companies relying on public procurement contracts, as timely payments are essential for reinvestment and job creation.
Public Procurement and Supporting Domestic Manufacturers
A key aspect of AMELAF’s strategy involves advocating for government procurement policies that prioritize Mexican pharmaceutical companies. Ocampo emphasized the need for public purchasing to benefit these businesses, ensuring a consistent capital flow for continued growth and innovation. This aligns with the government’s existing Plan Mexico initiatives aimed at increasing domestic content and substituting imports.
A Strong Foundation: Domestic Production Capacity
Mexico’s domestic pharmaceutical manufacturers already play a substantial role in the country’s healthcare system. Over the past nine years, they have supplied 75% of the units used in the public health system and 60% of those in the regulated private market. This demonstrates a significant existing capacity and a strong foundation for further expansion.
The $400 Billion Opportunity
The Mexican pharmaceutical market represents a substantial opportunity, with public purchases reaching nearly 400 billion pesos every two years. Secretary of Health, David Kershenobich, highlighted this potential, emphasizing the economic contribution of the industry and the possibilities for further development through collaborative efforts.
Biosimilars and Generic Medications: A Vital Component
Ocampo underscored the importance of generic medications, stating, “There is no public health system that can exist without them. They allow maintaining coverage, controlling spending, and treating massive populations.” She envisions Mexico developing an ecosystem similar to those in Asia, encompassing small, medium, and large companies dedicated to the production of biosimilars, natural products, and other essential medications.
Government Support and Collaborative Partnerships
The government, through the Secretariat of Health, has signaled its commitment to supporting the industry. Subsecretary Eduardo Clark García Dobarganes announced plans to facilitate the participation of Mexican companies in the upcoming 2027-2028 consolidated purchase of medications and medical supplies. However, he also urged companies to make only commitments they can fulfill, offering competitive prices, and maintaining a transparent and competitive environment.
Strengthening the API Supply Chain
A critical area for development is the production of Active Pharmaceutical Ingredients (APIs) – the raw materials used in drug manufacturing. Modernizing processes, advancing regulation, and leveraging local capabilities for API production are key priorities identified by the Secretariat of Health.
FAQ
Q: What is AMELAF’s main goal for the next few years?
A: AMELAF aims to position the Mexican pharmaceutical industry as a major export power and a key contributor to the national economy.
Q: What is the government’s role in supporting this growth?
A: The government is focused on streamlining regulations, prioritizing Mexican companies in public procurement, and fostering a collaborative environment.
Q: Why are generic medications so important?
A: Generic medications are essential for maintaining affordable healthcare access and treating large populations.
Q: What is the estimated value of the public pharmaceutical market in Mexico?
A: The public pharmaceutical market is valued at approximately 400 billion pesos every two years.
Did you know? Mexico’s domestic pharmaceutical manufacturers currently supply 75% of the units used in the public health system.
Pro Tip: Companies looking to invest in the Mexican pharmaceutical sector should focus on areas where regulatory streamlining is a priority, such as biosimilar and generic drug production.
Explore more articles on Mexico’s economic landscape and the pharmaceutical industry.
Subscribe to our newsletter for the latest updates and insights!
